Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial

Frederick L Moffat, C. M. Pinsky, L. Hammershaimb, N. J. Petrelli, Y. Z. Patt, F. S. Whaley, D. M. Goldenberg

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Purpose: To assess the performance and the potential clinical impact of a new antibody imaging agent, CEA-Scan (Immunomedics Inc, Morris Plains, NJ), in 210 presurgical patients with advanced recurrent or metastatic colorectal carcinomas. Methods: CEA-Scan, an anti-carcinoembryonic antigen (CEA) Fab' antibody fragment labeled with technetium-99m-pertechnetate (99mTc), was injected intravenously (IV), and external scintigraphy was performed 2 to 5 and 18 to 24 hours later. Imaging with conventional diagnostic modalities (CDM) was also performed, and findings were confirmed by surgery and histology. Results: The sensitivity of CEA-Scan was superior to that of CDM in the extrahepatic abdomen (55% v 32%; P = .007) and pelvis (69% v 48%; P = .005), and CEA-Scan findings complemented those of CDM in the liver. Among 122 patients with known disease, the positive predictive value was significantly higher when both modalities were positive(98%) compared with each alone (68% to 70%), potentially obviating the need for histologic confirmation when both tests are positive. Imaging accuracy also was significantly improved by adding CEA-Scan to CDM. In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan combined with CDM (61% v 33%). Potential clinical benefit from CEA-Scan was demonstrated in 89 of 210 patients. Only two patients developed human antimouse antibodies (HAMA) to CEA-Scan after a single injection, and none of 19 assessable patients after two injections. Conclusion: CEA-Scan affords high-quality, same-day imaging, uses an inexpensive and readily available radionuclide, adds clinically significant information in assessing extent and location of disease in colorectal cancer patients, and only rarely induces a HAMA response.

Original languageEnglish
Pages (from-to)2295-2305
Number of pages11
JournalJournal of Clinical Oncology
Volume14
Issue number8
StatePublished - Aug 23 1996

Fingerprint

Immunoglobulin Fragments
Immunoglobulin Fab Fragments
Carcinoembryonic Antigen
Technetium
Rectum
Colon
Carcinoma
Colorectal Neoplasms
IMMU-4 monoclonal antibody
Sodium Pertechnetate Tc 99m
Injections
Antibodies
Pelvis
Radioisotopes
Radionuclide Imaging
Abdomen
Antibody Formation
Histology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum : Results of a pivotal, phase III trial. / Moffat, Frederick L; Pinsky, C. M.; Hammershaimb, L.; Petrelli, N. J.; Patt, Y. Z.; Whaley, F. S.; Goldenberg, D. M.

In: Journal of Clinical Oncology, Vol. 14, No. 8, 23.08.1996, p. 2295-2305.

Research output: Contribution to journalArticle

@article{208573644bef49549825f0a91498da10,
title = "Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial",
abstract = "Purpose: To assess the performance and the potential clinical impact of a new antibody imaging agent, CEA-Scan (Immunomedics Inc, Morris Plains, NJ), in 210 presurgical patients with advanced recurrent or metastatic colorectal carcinomas. Methods: CEA-Scan, an anti-carcinoembryonic antigen (CEA) Fab' antibody fragment labeled with technetium-99m-pertechnetate (99mTc), was injected intravenously (IV), and external scintigraphy was performed 2 to 5 and 18 to 24 hours later. Imaging with conventional diagnostic modalities (CDM) was also performed, and findings were confirmed by surgery and histology. Results: The sensitivity of CEA-Scan was superior to that of CDM in the extrahepatic abdomen (55{\%} v 32{\%}; P = .007) and pelvis (69{\%} v 48{\%}; P = .005), and CEA-Scan findings complemented those of CDM in the liver. Among 122 patients with known disease, the positive predictive value was significantly higher when both modalities were positive(98{\%}) compared with each alone (68{\%} to 70{\%}), potentially obviating the need for histologic confirmation when both tests are positive. Imaging accuracy also was significantly improved by adding CEA-Scan to CDM. In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan combined with CDM (61{\%} v 33{\%}). Potential clinical benefit from CEA-Scan was demonstrated in 89 of 210 patients. Only two patients developed human antimouse antibodies (HAMA) to CEA-Scan after a single injection, and none of 19 assessable patients after two injections. Conclusion: CEA-Scan affords high-quality, same-day imaging, uses an inexpensive and readily available radionuclide, adds clinically significant information in assessing extent and location of disease in colorectal cancer patients, and only rarely induces a HAMA response.",
author = "Moffat, {Frederick L} and Pinsky, {C. M.} and L. Hammershaimb and Petrelli, {N. J.} and Patt, {Y. Z.} and Whaley, {F. S.} and Goldenberg, {D. M.}",
year = "1996",
month = "8",
day = "23",
language = "English",
volume = "14",
pages = "2295--2305",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum

T2 - Results of a pivotal, phase III trial

AU - Moffat, Frederick L

AU - Pinsky, C. M.

AU - Hammershaimb, L.

AU - Petrelli, N. J.

AU - Patt, Y. Z.

AU - Whaley, F. S.

AU - Goldenberg, D. M.

PY - 1996/8/23

Y1 - 1996/8/23

N2 - Purpose: To assess the performance and the potential clinical impact of a new antibody imaging agent, CEA-Scan (Immunomedics Inc, Morris Plains, NJ), in 210 presurgical patients with advanced recurrent or metastatic colorectal carcinomas. Methods: CEA-Scan, an anti-carcinoembryonic antigen (CEA) Fab' antibody fragment labeled with technetium-99m-pertechnetate (99mTc), was injected intravenously (IV), and external scintigraphy was performed 2 to 5 and 18 to 24 hours later. Imaging with conventional diagnostic modalities (CDM) was also performed, and findings were confirmed by surgery and histology. Results: The sensitivity of CEA-Scan was superior to that of CDM in the extrahepatic abdomen (55% v 32%; P = .007) and pelvis (69% v 48%; P = .005), and CEA-Scan findings complemented those of CDM in the liver. Among 122 patients with known disease, the positive predictive value was significantly higher when both modalities were positive(98%) compared with each alone (68% to 70%), potentially obviating the need for histologic confirmation when both tests are positive. Imaging accuracy also was significantly improved by adding CEA-Scan to CDM. In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan combined with CDM (61% v 33%). Potential clinical benefit from CEA-Scan was demonstrated in 89 of 210 patients. Only two patients developed human antimouse antibodies (HAMA) to CEA-Scan after a single injection, and none of 19 assessable patients after two injections. Conclusion: CEA-Scan affords high-quality, same-day imaging, uses an inexpensive and readily available radionuclide, adds clinically significant information in assessing extent and location of disease in colorectal cancer patients, and only rarely induces a HAMA response.

AB - Purpose: To assess the performance and the potential clinical impact of a new antibody imaging agent, CEA-Scan (Immunomedics Inc, Morris Plains, NJ), in 210 presurgical patients with advanced recurrent or metastatic colorectal carcinomas. Methods: CEA-Scan, an anti-carcinoembryonic antigen (CEA) Fab' antibody fragment labeled with technetium-99m-pertechnetate (99mTc), was injected intravenously (IV), and external scintigraphy was performed 2 to 5 and 18 to 24 hours later. Imaging with conventional diagnostic modalities (CDM) was also performed, and findings were confirmed by surgery and histology. Results: The sensitivity of CEA-Scan was superior to that of CDM in the extrahepatic abdomen (55% v 32%; P = .007) and pelvis (69% v 48%; P = .005), and CEA-Scan findings complemented those of CDM in the liver. Among 122 patients with known disease, the positive predictive value was significantly higher when both modalities were positive(98%) compared with each alone (68% to 70%), potentially obviating the need for histologic confirmation when both tests are positive. Imaging accuracy also was significantly improved by adding CEA-Scan to CDM. In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan combined with CDM (61% v 33%). Potential clinical benefit from CEA-Scan was demonstrated in 89 of 210 patients. Only two patients developed human antimouse antibodies (HAMA) to CEA-Scan after a single injection, and none of 19 assessable patients after two injections. Conclusion: CEA-Scan affords high-quality, same-day imaging, uses an inexpensive and readily available radionuclide, adds clinically significant information in assessing extent and location of disease in colorectal cancer patients, and only rarely induces a HAMA response.

UR - http://www.scopus.com/inward/record.url?scp=9444289885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444289885&partnerID=8YFLogxK

M3 - Article

C2 - 8708720

AN - SCOPUS:9444289885

VL - 14

SP - 2295

EP - 2305

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -